Changes in hepatic content of these metabolites are associated with a corresponding decline in the NASH gene expression markers, i.e., MCP1, CD68, ProCOL1A1, NOX2, SCD1 and TLR4. The gene discussed is CD68; the disease is metabolic dysfunction-associated steatohepatitis.